Resona Asset Management Co. Ltd. Has $8.38 Million Stock Position in United Therapeutics Corporation $UTHR

Resona Asset Management Co. Ltd. cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 6.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,142 shares of the biotechnology company’s stock after selling 1,140 shares during the period. Resona Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $8,381,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Torren Management LLC bought a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter worth about $31,000. Wilmington Savings Fund Society FSB boosted its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics during the fourth quarter worth about $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 14,440 shares of United Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 559,913 shares of company stock worth $311,962,531. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Up 0.3%

UTHR stock opened at $565.87 on Friday. The business’s 50-day moving average price is $562.78 and its two-hundred day moving average price is $511.17. The firm has a market cap of $24.02 billion, a PE ratio of 20.89, a P/E/G ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.63 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.